Systems biology–based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma-Reference-Cited by-同舟云学术

Systems biology–based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma

Published:2018-10-24 Issue:464 Volume:10 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Huang Lei¹^ORCID,Garrett Injac Sarah²³^ORCID,Cui Kemi¹^ORCID,Braun Frank²,Lin Qi²,Du Yuchen²,Zhang Huiyuan²,Kogiso Mari²,Lindsay Holly²³,Zhao Sibo²³,Baxter Patricia²³,Adekunle Adesina⁴,Man Tsz-Kwong³,Zhao Hong¹,Li Xiao-Nan²³^ORCID,Lau Ching C.³,Wong Stephen T. C.¹^ORCID

Affiliation:

1. Department of Systems Medicine and Bioengineering, Houston Methodist Research Institute and Cancer Center, Weill Cornell Medicine, Houston, TX 77030, USA.

2. Preclinical Neuro-Oncology Research Program, Baylor College of Medicine, Houston, TX 77030, USA.

3. Texas Children’s Cancer and Hematology Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.

4. Department of Pathology, Texas Children’s Hospital, Houston, TX 77030, USA.

Abstract

Systematic drug repositioning identifies digoxin as a potential treatment for groups 3 and 4 medulloblastoma.

Funder

National Institutes of Health

Cancer Prevention and Research Institute of Texas

Cancer Fighters of Houston

Ting Tsung and Wei Fong Chao Foundation

John S Dunn Research Foundation

Virginia and L.E. Simmons Foundation and Cancer Fighters of Houston